Skip to main content

11-02-2019 | Rheumatoid arthritis | Editorial | Article

20 years of TNF inhibitors in rheumatoid arthritis

Author: Peter C Taylor

Learning objectives


The past quarter century has witnessed unprecedented advances in our understanding of the pathophysiology of rheumatoid arthritis (RA). Fortunately, for the majority of patients with this disease, the current outlook is significantly improved when compared with a generation earlier [1]. Even so, RA continues to have a substantial impact on the quality of life of many patients [2]. Several factors have contributed to the dramatic changes in the management of RA over this time period, but arguably most notable was the approval two decades ago and subsequent clinical availability of biologic inhibitors of tumor necrosis factor (TNF).

The role of tumor necrosis factor in rheumatoid arthritis

TNF itself is pleiotropic, with multiple functions including immune regulation and pro-inflammatory roles. Biological effects of TNF on responder cells are mediated via binding to one of two different receptors, TNF receptor (TNFR) I or TNFRII, with subsequent activation of different signal transduction pathways and consequently distinct effects. In the context of the rheumatoid joint, where TNF is overexpressed and dysregulated, these effects include synovial proliferation and angiogenesis as well as regulation of other proinflammatory mediators, which include various cytokines, prostaglandins, and matrix metalloproteinases [3]. Consequently, TNF plays an important role in articular tissue destruction as well as contributing to periarticular osteoporosis, which is an early characteristic of RA.

Development of the first biologic therapies for rheumatoid arthritis

Two concurrent advances in the 1980s are considered responsible for the evolution of biologic treatments in the management of RA. First, the development of new methodologies, allowing cataloging of cytokines in rheumatoid joint tissue, brought about the identification of TNF as a dominant pro-inflammatory molecule and potential therapeutic target. Second, a breakthrough in protein engineering resulted in production of clinical grade antibodies, or engineered derivatives, necessary to validate the hypothesis that TNF was a cytokine of relevance to the pathology of RA.

Preclinical data

The identification of TNF as a key cytokine and potential therapeutic target in RA came about as a result of studying synovial tissue donated by RA patients with active disease. At this time, fewer effective drugs were available, and therefore synovial tissue tended to be more floridly inflamed in these patients. Further supporting evidence consistent with these findings emerged from studies of preclinical murine models [4].

Clinical data

Confirmatory evidence of the pathogenic role of TNF came when proof of concept clinical trials demonstrated an unequivocal amelioration of signs and symptoms in a majority of patients treated with TNF inhibitors [5]. And perhaps most strikingly, when used in combination with concomitant methotrexate, biologic TNF inhibition was found to abrogate radiographic progression; previously considered an inexorably progressive feature of RA [6]. The most impressive benefits of biologic TNF inhibitors have been demonstrated when therapy is initiated in the earliest stages of RA [7–9]. This is perhaps not surprising, given that preservation of function is dependent on both reduction in disease activity and prevention of joint damage. Once damage is established as RA progresses, this component is generally not reversible.

Risk for adverse effects


While TNF inhibitors have proven to be highly effective, target-related toxicity remains an ever-present concern. Risk of infectious complications, with a particular concern regarding intracellular pathogens, was predictable given knowledge of TNF biology. During early use of TNF inhibitors, cases of tuberculosis were reported in approximately 1 in 1000 patients, however routine screening prior to initiation of biologic has significantly reduced this rate [10].


Other theoretical concerns included the role of TNF in tumor surveillance, and potential toxicities associated with long-term TNF inhibition. However, after two decades of clinical experience with biologic TNF inhibitors, no evidence has been found to suggest that this class of biologics increases risk of lymphoma [11,12]. Although there is an increased risk of lymphoma in patients with RA treated with TNF inhibitors, as compared with healthy controls, current thinking suggests that it is the total inflammatory burden over time that predisposes these patients to increased risk of lymphoma, rather than the treatment intervention [13]. This is consistent with the observed early data to emerge from various national registries which were largely comprised of RA patients with persistently high levels of disease activity prior to starting treatment with a TNF inhibitor.

Development of new biologic therapies

The early, positive experience in the use of biologic TNF inhibitors in RA led to a rapid expansion in this class of drugs, and a subsequent extension of therapeutic indications into a wide range of chronic inflammatory disorders with concomitant, unprecedented commercial success. This paved the way for a broader revolution in development of biologic therapies targeting other cytokines and immune cells, and consequently, a greatly expanded therapeutic armamentarium for the treatment of RA. In monotherapy, interleukin-6 receptor (IL-6R) blockade has been shown to have superior efficacy for symptoms and signs [14,15]. However, when used in combination with methotrexate, no biologic of different mechanism of action has proved more efficacious than TNF inhibitors.


Prohibitively high drug costs of biologic TNF inhibitors have been to the considerable detriment of healthcare economies, and disincentivized earlier and more optimally effective use of TNF inhibitors. However, as the first generation of biologic anti-TNF “originators” have come off patent, biosimilars of infliximab, etanercept, and adalimumab have emerged, with a corresponding improvement in cost-effectiveness. Strict regulatory definitions of “biosimilarity” have been designed to ensure that any post-translational modifications of the primary amino acid sequence, which is identical to that of the originator, still give rise to highly similar efficacy outcomes without the penalty of newly arising adverse events. To date, clinical experience with biosimilars, particularly in Europe [16], has been very favorable, and has resulted in significant savings for the healthcare economies adopting them.


Two decades of clinical experience with biologic TNF inhibitors in the management of RA have confirmed a favorable benefit: risk profile. While not without associated adverse effects, particularly infection, these biologic therapies have a remarkable overall safety record [17]. In spite of all of these welcome advances, many unmet needs remain for people living with RA [2]. These include primary non-response in a significant minority of patients and a high rate of secondary loss of response over time. This may in part be related to a fundamental challenge associated with biologic drugs, namely immunogenicity of administered protein. Furthermore, in established, conventional synthetic DMARD-refractory RA, where TNF inhibitors are most widely used, the desirable treatment target of remission remains aspirational for the majority of patients [18]. And although a new generation of efficacious small molecular, orally available therapies is now impacting on RA management [19], it looks likely that TNF inhibitors will continue to play a major role in the therapeutic armamentarium for the foreseeable future.

About the author

Peter Taylor

Peter Taylor holds the Norman Collison chair of musculoskeletal sciences, and is the Head of Clinical Sciences at the Botnar Research Centre within the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, and a Fellow of St Peter’s College at the University of Oxford, UK. Disclosures

Full biography

  1. Taylor PC. Developing anti-TNF and biologic agents. Rheumatology (Oxford) 2011; 50: 1551–1353.
  2. Taylor PC, Moore A, Vasilescu R, Alvir J, Tarallo M. A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspective. Rheumatol Int 2016; 36: 685–695.
  3. Taylor PC, Feldman M. Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nat Rev Rheumatol 2009; 5: 578–582.
  4. Feldmann M, Maini RN. Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat Med 2003; 9: 1245–1250.
  5. Elliott MJ, Maini RN, Feldmann M et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344: 1105–1110.
  6. Emery P, Genovese MC, van Vollenhoven R et al. Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis. J Rheumatol 2009; 36: 1429–1441.
  7. Breedveld FC, Weisman MH, Kavanaugh AF et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006; 54: 26–37.
  8. St Clair EW, van der Heijde DM, Smolen JS et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004; 50: 3432–3443.
  9. Emery P, Breedveld FC, Hall S et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2008; 372: 375–382.
  10. Keane, J. TNF-blocking agents and tuberculosis: new drugs illuminate an old topic. Rheumatology (Oxford) 2005; 44: 714–720.
  11. Wolfe F, Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum 2007; 56: 1433–1439.
  12. Askling J, Baecklund E, Granath F et al. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Ann Rheum Dis 2009; 68: 648–653.
  13. Baecklund E, Iliadou A, Askling J et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006; 54: 692–701.
  14. Gabay C, Emery P, van Vollenhoven R et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 2013; 381: 1541–1550.
  15. Burmester GR, Lin Y, Patel R et al. Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. Ann Rheum Dis. 2017; 76: 840–847.
  16. Taylor PC. A scientific update on biosimilar infliximab (CT-P13) in rheumatic diseases. Expert Rev Clin Immunol 2015; 11(Suppl 1): S1–4.
  17. Askling J, Dixon W. The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis. Curr Opin Rheumatol. 2008; 20: 138–144.
  18. PC Taylor, R Alten, Gomez Reino JJ et al. Factors influencing use of biologic therapy and adoption of treat-to-target recommendations in current European rheumatology practice. Patient Prefer Adherence 2018; 12: 2007–2014.
  19. Taylor PC. Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis. Rheumatology (Oxford) 2018 In press.

Related content

22-03-2018 | Biosimilars | Editorial | Article

Biosimilars: The price is not right